Background: Chronic hepatitis C virus (HCV) infection is prevalent in dialysis patients, and standard interferon monotherapy is the current standard of care for such patients.
Aim: To investigate whether pegylated interferon has a better therapeutic efficacy and safety profile than standard interferon in dialysis patients with chronic hepatitis C.
Methods: A total of 50 such patients were randomly assigned to receive either pegylated interferon alfa-2a 135 μg subcutaneously once per week or standard interferon alfa-2a 3 million units subcutaneously thrice per week for 24 weeks. The primary efficacy and safety end points were sustained virologic response (SVR) by intention-to-treat analysis and treatment-related withdrawal rate during the study.
Results: In univariate analysis, patients with pegylated interferon alfa-2a tended to have a higher SVR than those with standard interferon alfa-2a (48% vs. 20%, p = 0.07). By using multivariate analysis, treatment with pegylated interferon alfa-2a (p = 0.02) and pre-treatment HCV RNA level < 800,000 IU/ml (p = 0.007) were independently predictive of SVR. All patients failing to achieve rapid virologic response (RVR) could not achieve SVR. In addition, patients receiving pegylated interferon alfa-2a had a significantly lower treatment-related withdrawal rate than those receiving standard interferon alfa-2a (0% vs. 20%, p = 0.04).
Conclusions: Pegylated interferon alfa-2a once weekly provides more effective and safer therapy than standard interferon alfa-2a thrice weekly for treatment-naïve dialysis patients with chronic hepatitis C. (ClinicalTrials.gov number, NCT00172809)
- chronic hepatitis C
- pegylated interferon
- standard interferon
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.